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Human pluripotent stem cells (hPSCs) are potential
sources of cells for modeling disease and develop-
ment, drug discovery, and regenerative medicine.
However, it is important to identify factors that may
impact the utility of hPSCs for these applications. In
an unbiased analysis of 205 hPSC and 130 somatic
samples, we identified hPSC-specific epigenetic
and transcriptional aberrations in genes subject
to X chromosome inactivation (XCI) and genomic
imprinting, which were not corrected during directed
differentiation. We also found that specific tissue
types were distinguished by unique patterns of
DNA hypomethylation, which were recapitulated
by DNA demethylation during in vitro directed differ-
entiation. Our results suggest that verification of
baseline epigenetic status is critical for hPSC-
based disease models in which the observed pheno-
type depends on proper XCI or imprinting and that
tissue-specific DNA methylation patterns can be620 Cell Stem Cell 10, 620–634, May 4, 2012 ª2012 Elsevier Inc.accurately modeled during directed differentiation
of hPSCs, even in the presence of variations in XCI
or imprinting.
INTRODUCTION
hPSCs maintain the ability to self-renew indefinitely and can be
differentiated into a wide range of cell types, making them an
excellent source of differentiated cells for preclinical and clinical
applications. However, several studies have reported genetic,
epigenetic, and transcriptional variation among hPSC cultures
(Bock et al., 2011; Chin et al., 2009; Feng et al., 2010; Gore
et al., 2011; Hough et al., 2009; Hussein et al., 2011; Kim et al.,
2007; Laurent et al., 2011; Lister et al., 2011; Marchetto et al.,
2009; Ohi et al., 2011), which may affect their differentiation
propensities and utility for disease modeling, cell therapy, and
drug development (Bock et al., 2011; Pomp et al., 2011; Tchieu
et al., 2010; Urbach et al., 2010).
Epigenetic processes, including DNA methylation, histone
modifications, and noncoding RNA expression, act coordinately
to regulate cellular differentiation andhomeostasis. During devel-
opment, different cell types acquire distinct DNA methylation
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identity. For most genes, the pattern of DNA methylation is iden-
tical onboth alleles; atmore evolutionarily complex loci, including
imprinted andXchromosomegenes, however, only a single allele
is normally methylated.
Genomic imprinting is the mechanism by which monoallelic
expression is achieved in a parent-of-origin-specific fashion. At
least 60 human genes are known to be imprinted (http://www.
geneimprint.org) and can be further classified as ‘‘gametic’’
when the imprints are established in the germline or as ‘‘somatic’’
when they arise during early embryonic development as a result of
spreading of gametic imprints (reviewed in John and Lefebvre,
2011). Genomic imprints are particularly susceptible to environ-
mental factors (Dolinoy et al., 2007; Odom and Segars, 2010)
and imprinting defects are associated with developmental disor-
ders, including Silver-Russell, Beckwith-Wiedemann, and
Prader-Willi syndromes, as well as several human cancers (Bhu-
sari et al., 2011; Uribe-Lewis et al., 2011). Variability in imprinting
status has been reported for hPSCs (Adewumi et al., 2007; Frost
etal., 2011;Kimetal., 2007;Rugg-Gunnetal., 2007),but theextent
of this variation is unclear because of the limited number of im-
printed genes, cell lines, and cell types assayed in those studies.
X chromosome inactivation (XCI) refers to the transcriptional
repression of one of the two X chromosomes in female cells and
mediates dosage compensation between XY males and XX
females (reviewed in Kim et al., 2011). Transcription of a long non-
codingRNA,XIST (X-inactive specific transcript), hasa role in initi-
ating and maintaining XCI. In mice, female PSCs do not express
Xist and have two active X chromosomes (XaXa); upon differenti-
ation, Xist transcription is derepressed on a single X chromo-
some, resulting in inactivation of that chromosome (XaXi). The
processof XCI in humans also involvesXIST, but themechanisms
controlling its expression are fundamentally different than those
regulating Xist in mice (Migeon et al., 2002). Although the
‘‘normal’’ state of XCI in hPSCs remains controversial, almost all
reported female hPSC lines display some degree of XCI (Dvash
et al., 2010; Hall et al., 2008; Hoffman et al., 2005; Pomp et al.,
2011; Shen et al., 2008; Tchieu et al., 2010) with few exceptions
(Lengner et al., 2010; Marchetto et al., 2010; Hanna et al., 2010).
Previous studies of epigenetic stability and variation in hPSCs
have been limited in scope and resolution. Most have used
allele-specific expression of selected imprinted genes (Adewumi
et al., 2007; Frost et al., 2011; Kim et al., 2007; Rugg-Gunn et al.,
2007), restriction landmark genome scanning of a small portion
of the genome (Allegrucci et al., 2007), or XIST expression to infer
the overall epigenetic status of a small number of hESC samples
(Hall et al., 2008; Shen et al., 2008; Silva et al., 2008). To obtain
a comprehensive view of hPSC-specific epigenomic patterns,
we collected 136 hESC and 69 hiPSC samples representing
more than 100 cell lines for analysis. In order to establish ex-
pected variation in human tissues, we collected 80 high-quality
and well-replicated samples representing 17 distinct tissue
types frommultiple individuals. Finally, we selected 50 additional
samples from primary cell lines of diverse origin to control for any
aberrations that may arise as a general, non-hPSC-specific,
consequence of in vitro manipulation. With these samples, we
performed genome-wide DNA methylation and mRNA expres-
sion profiling by using the Illumina Infinium 27K and 450K DNA
Methylation BeadChips (27K and 450K DNA Methylation array)as well as the Illumina HT12v3 Gene Expression BeadArray.
These platforms interrogate DNA methylation at 27,578 CpG
sites associated with 14,500 well-annotated genes (27K DNA
Methylation array), >450,000 CpG sites associated with both
coding and noncoding genes (450K DNA Methylation array)
(Sandoval et al., 2011), and the expression of more than
30,000 mRNA transcripts (HT12v3). The Illumina DNA methyla-
tion and gene expression array platforms have been shown to
correlate well with whole-genome bisulfite sequencing (Laurent
et al., 2010) and qRT-PCR results (Kuhn et al., 2004), respec-
tively. A summary of samples and analyses performed are
detailed in Table S1 available online.
RESULTS
Differential Global DNA Methylation in Pluripotent
and Somatic Cells
Our initial goal was to analyze the data in an unbiased manner, in
order to identify variations in DNAmethylation that were demon-
strated by the data, rather than our preconceptions about the
samples and/or DNA methylation. Preliminary clustering of all
samples and all probes resulted in separation of male and
female samples based on the methylation state of the X chromo-
some, consistent with our previous findings (Bibikova et al.,
2006). We therefore examined X chromosome and autosomal
probes separately.
We identified 3,499 autosomal CpG sites on the 27K DNA
Methylation array that were differentially methylated (Db > 0.2,
FDR < 0.01) between pluripotent and somatic (tissue and
primary) samples. In our initial analyses, we noticed that there
was a large degree of variability in DNA methylation both
between the pluripotent and somatic groups and within each
group. In order to dissect out these differences in detail, we
divided the CpG sites into three categories, which we clustered
separately: pluripotentLowVar/somaticLowVar, where the variability
was low in both the pluripotent and somatic groups (standard
deviation [SD] < 0.2; Figure 1A, Table S2A); pluripotentHighVar/
somaticLowVar, where variability was specific to hPSCs (SD > 0.2
in hPSCs, SD < 0.2 in somatic cells; Figure 1B, Table S2B); and
pluripotentLowVar/somaticHighVar, where variability was present in
the somatic samples but not the pluripotent samples (SD > 0.2
in somatic cells, SD < 0.2 in hPSCs; Figure 1C, Table S2C).
The CpG sites in the pluripotentLowVar/somaticLowVar category
were separated into seven clusters by hierarchical clustering
(Figure 1A). Each cluster was tested for functional enrichments
by the Genomic Regions Enrichment of Annotations Tool
(GREAT) (McLean et al., 2010), but only one cluster showed
significant enrichments. This cluster was fully methylated in
pluripotent samples, partially methylated in somatic samples,
and significantly enriched for genes associated with purinergic
nucleotide receptor activity and genomic imprinting. The enrich-
ment of imprinted regions in this group demonstrates that
a subset of imprinted genes is consistently hypermethylated in
hPSCs relative to somatic samples, suggesting a difference in
the regulation of imprinted genes between hPSCs and somatic
cells. DNA methylation and gene expression were anticorrelated
(R < 0.50) for many of these genes (Figures S1A and S1B).
The CpG sites in the pluripotentHighVar/somaticLowVar category
clustered into two groups. One group was enriched forCell Stem Cell 10, 620–634, May 4, 2012 ª2012 Elsevier Inc. 621
Figure 1. Differential DNA Methylation in Pluripotent and Somatic
Cells
Data for CpG sites differentially methylated between pluripotent and somatic
cells (Db > 0.2) on the 27K DNA Methylation array are shown.
(A) PluripotentLowVar/somaticLowVar: 1,432 CpGs for 1,282 genes with low
variation (SD < 0.2) within both the pluripotent and somatic sample groups. The
seven clusters of CpGs that were examined with the GREAT algorithm are
shaded on the left.
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(Figure 1B). This enrichment (i.e., genes with KLF binding sites)
is interesting because of the use of KLF4 in reprogramming
(Takahashi et al., 2007) and KLF2 in converting hESCs to a
mouse ESC-like phenotype (Hanna et al., 2010). The second
group was also enriched for genomic imprinting, demonstrating
that a second subset of imprinted genes is variable specifically in
hPSCs.
The pluripotentLowVar/somaticHighVar category contained
several clusters of CpG sites that were hypermethylated in all of
the hPSCsand themajority of somatic samples but unmethylated
inasmall numberof somatic samplescontaining relatedcell types
(Figure 1C). Thegenesassociatedwith eachcluster ofCpGswere
enriched for functional categories related to the known functions
of the corresponding samples (Figures S1C–S1G). For example,
CpG sites that were uniquely hypomethylated in the blood,
spleen, and lymph node samples were enriched for the immune
system process, immune response, and defense response cate-
gories (Figure S1G). Because these genes were uniformly hyper-
methylated in the pluripotent state and in unrelated somatic cell
types, it appeared that cell type-specific genes underwent selec-
tive DNA demethylation during differentiation and led us to
explore this phenomenon at higher resolution.
DNA Hypomethylation Distinguishes Human Tissues
To achieve higher resolution, we analyzed a subset of 153 hPSC
and tissue samples with the 450K DNA Methylation array. In
order to identify unique epigenetic features in 17 distinct tissue
types (e.g., brain, heart, kidney) and hPSCs, we filtered for
CpGs that were differentially methylated in each tissue or cell
type compared to all other samples with a Db > 0.5 (p < 0.05).
Consistent with our previous results, DNA hypomethylation
was the most discriminate epigenetic feature of any given tissue
(Figure 2A; Table S3). For a majority of these tissue-specific
groups of hypomethylated genes, functional enrichments
via GREAT were also consistent with the particular tissue’s
function and/or cellular composition (Figure 2B). Interestingly,
approximately 20% (2,554/12,254) of these hypomethylated
CpGs were associated with transcription factors (according to
region-gene associations in GREAT). Among these, CpGs
associated with POU5F1 and NANOG, which are known master
regulators of pluripotency and are among the six transcription
factors commonly used in reprogramming, were hypomethy-
lated specifically in hPSCs (Figure 2C). Additionally, CpGs
associated with the neural lineage transcription factors MYT1L,
POU3F3, SOX1, and MYT1 were specifically hypomethylated
in brain samples. In fact, MYT1L is one of four required
factors for the direct conversion of fibroblasts into neurons
(Pang et al., 2011), and POU3F3 (BRN1) is a closely related func-
tional homolog of another neuronal transdifferentiation factor,
POU3F2 (BRN2) (Figure 2C).(B) PluripotentHighVar/somaticLowVar: 303 CpGs for 234 genes with variable
methylation only in the pluripotent group (SD > 0.2).
(C) PluripotentLowVar/somaticHighVar: 1,691 CpGs for 1,442 genes with variable
methylation only in the somatic group.
The color scale for the b values is shown. The distribution of sample types are
indicated below each heatmap, with hESCs in black, hiPSCs in yellow, and
somatic cells in red. See also Figure S1 and Table S2.
Figure 2. Tissue-Specific Patterns of DNA Methylation
Data for CpG sites on the 450K DNAMethylation array that were differentially methylated between samples from a given tissue and all other samples (Db > 0.5) are
shown.
(A) The histogram shows the fold difference in total number of uniquely hypomethylated and hypermethylated CpGs for a given tissue (listed in Table S3). If
hypomethylated CpGs predominate, the bar is green; if hypermethylated CpGs predominate, the bar is red. The total number of unique CpGs that were
differentially methylated in the given tissue type is shown above each bar, and the total number of samples per tissue type is shown on the x axis.
(B) 12,254 CpGs on the 450K DNA Methylation array with uniquely hypomethylated CpGs in specific tissue types. Functional enrichments for tissue-specific
hypomethylated clusters are identified with boxes. Samples are grouped according to hierarchical clustering and CpGs are rank-ordered for each tissue (see also
Table S3).
(C) DNA methylation of pluripotency- and neural-specific transcription factor genes.
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during Directed Differentiation
Based on the observation of tissue-specific patterns of DNA
hypomethylation and the assumption that epigenetic patterns
in hPSCs represent those of the early human embryo, we
reasoned that DNA demethylation was a normal component of
cellular differentiation. To test this hypothesis, we profiled three
hPSC lines before and after in vitro directed differentiation into
NESTIN/PAX6+ neural progenitor cells (NPCs; Figure 3A) and
mixed populations of A2B5/OLIG1+ oligodendroctye precursor
cells (OPCs; Figure 3B) and GALC+ oligodendrocytes (Figure 3C)
via established methods (Harness et al., 2011; Nistor et al.,
2005). Using 1,303 CpGs that were differentially methylated in
OPCs or NPCs compared to hPSCs and to all nonbrain tissues,
hierarchical clustering of these differentiated samples, hPSCs,
and tissues clearly distinguished NPCs, OPCs, and brain
samples from hPSCs and all other tissues (Table S4; Figure S2A).
Demethylation of several genes known to regulate oligodendro-
cyte differentiation including SKI, QKI, and OLIG2 (Aberg
et al., 2006; Atanasoski et al., 2004; Zhou and Anderson, 2002)
and the myelin proteins PLP1 and PMP22 (Figure 3D) was
observed and reflected in the GREAT enrichments for myelina-
tion and regulation of action potentials in neurons (Figure S2A).
Methylation of MYT1L was maintained during differentiation
from hPSCs to NPCs but was subsequently lost in the more
mature OPCs. In contrast to the NPCs and 15-week fetal brain,
DNA methylation of the PAX6 promoter region was evident in
OPCs, 18- to 20-week fetal brain, and adult brain (Figures 3D
and 3E). This successive gain of methylation at the PAX6 locus
was consistent with oligodendroglial commitment in OPCs and
the restricted neurogenic capacity of the adult brain and led
to the functional enrichments for neuron fate commitment
and motor neuron cell fate specification in the GREAT analysis
(Figure S2B).
Aberrant DNAMethylation at Imprinted Loci Is Prevalent
in hPSCs
Because our unbiased analyses showed frequent differences in
DNA methylation in regions of genomic imprinting between
hPSCs and somatic samples, as well as variability in these
regions among hPSC samples, we examined imprinted loci
separately. We identified 49 CpGs from the 27K DNA Methyla-
tion array that were assigned to known imprinted genes (http://
www.geneimprint.org) and also displayed methylation patterns
consistent with gametic imprints (Figure 4A). These loci were
partially methylated in tissue samples and were reciprocally
methylated in gynogenetic samples (our parthenogenetic
hESCs and previously published data from an ovarian teratoma;
Choufani et al., 2011) and androgenetic samples (previously
published data from hydatidiform moles; Choufani et al.,
2011) (Table S5A; Figures S3A–S3D; Experimental Procedures).
Analysis of the DNA methylation status of these imprinted
CpGs in pluripotent cells compared to somatic cells showed
recurrent hypermethylation of CpGs associated with the
genes DIRAS3, NAP1L5, MEST, H19, and ZIM2/PEG3. In a
small number of hPSC samples, hypomethylation occurred in
PLAGL1 andGRB10. ForGNAS, somehPSCsshowed agynoge-
netic pattern, whereas other hPSCs showed an androgenetic
pattern.624 Cell Stem Cell 10, 620–634, May 4, 2012 ª2012 Elsevier Inc.Hypermethylation and Hypomethylation at Imprinted
Loci in hPSCs Correlate with Loss of Allele-Specific
Gene Expression
In order to study the effects of reprogramming and time in culture
on epigenetic stability, we generated 11 hiPSC clones from fibro-
blasts and 4 hiPSC clones from chondrocytes. We collected
samples for analysis from the parental fibroblast and chondro-
cyte populations, early-passage samples from both chondro-
cyte and fibroblast-derived hiPSC clones, and late-passage
samples from the fibroblast-derived hiPSC clones. All clones
were shown to be pluripotent as demonstrated by immunocyto-
chemistry for pluripotency markers, in vitro differentiation,
teratoma formation, silencing of reprogramming factors, and
PluriTest (Figure S4; Table S1; Mu¨ller et al., 2011). For these
analyses, we identified 214 CpGs on the 450K DNA Methylation
array that had DNAmethylation patterns consistent with gametic
imprinting according to patterns observed in hydatidiform
mole, parthenogenetic hESC, and tissue samples (Experimental
Procedures; Table S5B). DLGAP2, KCNK9, MEG3, MKRN3,
ANKRD11, and PEG3/ZIM2 were hypermethylated in all hiPSC
clones relative to the parental samples, suggesting that these
aberrations occurred during reprogramming (Figure 4B). Hyper-
methylation ofH19 andGNASwas seen only in the late-passage
samples (in 8/11 and 1/11 fibroblast-derived clones, respec-
tively), pointing to instability at these loci with time in culture.
Losses in DNA methylation were also observed in HYMA1/
PLAGL1, GRB10, KCNQ1, SNRPN, andGNAS. Aberrant methyl-
ation of L3MBTL was present in 2/4 chondrocyte hiPSC clones.
Analysis of an additional 22 hPSC, 60 tissue, and 19 primary
samples identified additional aberrations in methylation of
DIRAS3, PEG10, and MEST in hPSCs and demonstrated the
relative stability of these loci in tissues and primary cell lines
(Figure S3E).
In order to determine whether the hypermethylation and hypo-
methylation we observed at imprinted loci resulted in loss of
imprinting, we examined allele-specific gene expression at
a subset of imprinted loci. We first used SNP genotyping data
we had previously obtained on our samples via theHumanOmni1
SNP genotyping microarray (Laurent et al., 2011) to identify
which of the samples contained informative heterozygous
SNPs in the PEG10 and PEG3 mRNAs. We then performed
allele-specific real-time polymerase chain reaction (RT-PCR) to
show that loss of DNAmethylation at the PEG10 locus correlated
with biallelic expression in the ESI051p37 hPSC sample and that
hypermethylation of PEG3 led to a total loss of gene expression
in several hPSC lines in comparison to the monoallelic expres-
sion observed in parental fibroblasts and an adult bladder
sample (Figures 4C and 4D). By using the HT12V3 mRNA
expression array, we also determined that CpG methylation
and mRNA expression were anticorrelated for MEG3, PEG3/
ZIM2, NAP1L5, NNAT, GNAS, NDN, H19, and SNRPN (Table
S5A). For many imprinted genes, our DNA methylation data
show similar frequencies of either stable or aberrant CpG
methylation compared to previous studies reporting on patterns
of allelic expression (Table S6; Adewumi et al., 2007; Allegrucci
et al., 2007; Frost et al., 2011; Kim et al., 2007; Rugg-
Gunn et al., 2007). However, forPEG3,MEG3, andH19, we iden-
tified frequent aberrant hypermethylation with corresponding
silencing of gene expression in hPSCs, in contrast to these
Figure 3. Directed Differentiation of hPSCs Recapitulates Epigenetic Hallmarks of Human Tissues
(A) Immunocytochemistry showing NESTIN and PAX6 staining in WA07-derived neural progenitor cells (NPCs) on day 22 of NPC differentiation.
(B) Immunostaining of A2B5 and OLIG1 in WA07-derived oligodendroctye precursor cells (OPCs) on day 42 of OPC differentiation.
(C) Immunostaining of GALC in WA07-derived oligodendrocytes on day 42 of OPC differentiation. Magnifications are indicated.
(D) DNA methylation (using the 450K DNA Methylation array) of select oligodendrocyte and neuronal genes in NPCs, OPCs, hPSCs, and tissues.
(E) Diagram of DNAmethylation patterns ofPAX6 in NPCs, OPCs, and brain samples corresponding to the chromosomal regions listed to the right of the heatmap
in (D).
Segments that are green are unmethylated and those that are red are methylated in the samples listed on the left. See also Figure S2 and Table S4.
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Figure 4. DNA Methylation of Imprinted Genes
Gene names highlighted in blue are paternally imprinted, pink arematernally imprinted, and green are isoform dependent. Hierarachical clusteringwas performed
for each group of samples (gynogenetic/androgenetic, hESCs, hiPSCs, somatic) independently. For each gene, CpG probes are ordered according to chro-
mosomal position.
(A) DNA methylation (27K DNA Methylation array) of 49 imprinted CpG sites showing a gametic imprint pattern in parthenogenetic, androgenetic, and tissue
samples.
(B) DNA methylation (450K DNAMethylation array) of 214 gametic imprinted CpG sites in source fibroblasts and chondrocytes, early-passage hiPSCs, and late-
passage hiPSCs.
(C and D) Allele-specific expression ofPEG10 andPEG3 in hPSC and somatic samples. hPSC samples are represented as squares, somatic samples as triangles,
and each data point is colored according to the average b value for that gene shown in the heatmap to the right. Genomic DNA and no template (NT) controls are
plotted as blue diamonds. Error bars indicate the standard error.
See also Figure S3.
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for these genes in hPSCs (Table S6; Adewumi et al., 2007;
Allegrucci et al., 2007; Frost et al., 2011; Kim et al., 2007;
Rugg-Gunn et al., 2007).
Specific Culture Conditions Are Associated with
Aberrant DNA Methylation of Certain Imprinted Genes
In order to determine whether the observed aberrations in
genomic imprints resulted from in vitro manipulations, we
selected 140 hPSC samples for which we had detailed histories
of culture media, passaging techniques, and growth substrates
(Table S7). For each imprinted gene (dependent variables), we
generated two separate multiple linear regressionmodels, which
in addition to the source lab, considered each in vitro manipula-
tion (independent variables) either in combination with other
concurrent in vitro manipulations (model 1; e.g., number of
manual passages in Wicell medium on MEFs) or in isolation
(model 2; e.g., number of passages in Wicell medium). Analysis
of these models showed apparent lab-specific effects for
DIRAS3, L3MBTL, and PEG3 (Bonferroni-adjusted p < 0.001;
Tables S7A–S7C). We constructed correlation matrices to inves-
tigate intervariable relationships that could potentially explain
these apparent lab-specific effects (Tables S7D and S7E).
DIRAS3 aberrations were most highly correlated with the A.L.L.
lab samples (R = 0.59), which was the only lab positively corre-
lated with use of the original medium used to maintain hESCs
(‘‘originalES,’’ R = 0.63) (Thomson et al., 1998). This lab-specific
effect can therefore be explained by the use of originalES
medium, which is the highest correlating variable with DIRAS3
aberrations (R = 0.82). L3MBTL aberrations were most signifi-
cantly correlated with the H.S.K. lab samples (R = 0.75). The
samples from the H.S.K. lab used in this analysis consisted of
two isogenic clones, which were both passaged in collagenase
and grown in Wicell-conditioned medium on Matrigel (R = 0.74).
Because these samples were nearly perfectly correlated with
these concurrent variables (R = 0.99), this lab-specific effect
for L3MBTL can almost entirely be explained by technique
and/or cell line of origin. The association of PEG3 aberrations
with the J.F.L. lab samples (Bonferroni adjusted p < 0.001,
R = 0.42) could not be attributed to any particular manipulation,
but most probably results from an overrepresentation of HDF51
hiPSC clones that were derived from the same fibroblast culture
in the same experiment and comprise 70% of all J.F.L. lab
samples in the model.
To determine whether hESC derivation methods may affect
imprinted gene methylation, we performed an independent anal-
ysis on 40 samples from 34 hESC lines that were derived in the
same lab from embryos of different quality, at varying days post-
fertilization (dpf) and via two different methods (bisection versus
whole embryo plating). The only correlation that we found was
that aberrations in the methylation status of PEG3 were weakly
associated with earlier dpf and whole embryo plating (Bonferroni
adjusted p < 0.05) (Table S7F).
XCI and XIST Expression Are Unstable in hPSCs
To assess the stability of XCI in our samples, we identified 293
CpGs on the X chromosome (using the 27K DNA Methylation
array) that were methylated in a manner consistent with XCI
in tissue samples (Experimental Procedures). Hierarchical clus-tering on the samples yielded five major sample clusters
(X-Cluster 1–X-Cluster 5), which are displayed with the CpGs
ordered according to chromosomal location in Figures 5A and
5B. All of the female somatic samples were in X-Cluster 5 and
had partial DNA methylation across the entire X chromosome,
consistent with the expected somatic female X-inactivated
(XaXi) state. X-Cluster 1 contained all of the male somatic and
male hPSC samples (which were, as expected, unmethylated
throughout the X chromosome), as well as one parthenogenetic
hESC line (LLC15) and samples from four female hESC lines
(SIVF024, SIVF028, SIVF029, and CM8) (Figures 5A and 5B).
SIVF024 was XO by SNP genotyping as evidenced by loss of
heterozygosity in the pseudoautosomal regions (Figure S5A)
and would be expected to have a male pattern of X chromosome
DNA methylation. However, SIVF028, SIVF029, and CM8 had
normal heterozygous XX SNP genotypes, indicating that they
contained two different X chromosomes (Figure S5A). Therefore,
the lack of DNA methylation on the X chromosome seen in these
samples was due to absence of XCI, rather than deletion of one
of the X chromosome. The remaining X-Clusters 4, 3, and 2 con-
tained female hPSC samples, with those in X-Cluster 4 showing
a uniform partially methylated pattern and possessing a slightly
higher level of methylation than the female somatic samples
(X-Cluster 5). The X-Clusters 2 and 3 samples lacked DNAmeth-
ylation in several noncontiguous regions of the X chromosome
(Figure 5B); this was specific to hPSCs and was not seen in
tissues or primary cell cultures (Figure S5C).
Examining the relationship between XIST expression and X
chromosome DNA methylation, we noted that there was a
relative threshold of XIST expression, above which we saw
uniform partial DNA methylation and below which we observed
decreased methylation in at least a subset of CpG sites (Fig-
ure 5C). This result was consistent with DNA methylation on
the chromosomal level (Figure 5B), where it was apparent that
the absence of DNAmethylation on the X chromosome occurred
in a patchy fashion.
XCI Is Maintained during Reprogramming
and Is Subsequently Lost with Time in Culture
We compared matched fibroblasts and 11 hiPSC clones
analyzed at early, intermediate, and late passages (Figures 5D
and 5E; Figure S5B) by using both the 27K and 450K DNA
Methylation arrays (Tables S5C and S5D). Shortly after reprog-
ramming, there was an increase in XIST expression and in overall
X chromosome DNA methylation. This was consistent with the
higher level of X chromosome DNA methylation seen in a subset
of female hPSC samples compared to the female somatic
samples (X-Cluster 4 and X-Cluster 5; Figure 5B). At later
passages, 8/11 hiPSC clones showed focal loss of XCI, indicated
by loss of DNA methylation and increased mRNA expression, in
the same regions observed in the hPSC collection as a whole
(Figure S5B). The 3/11 hiPSC clones that retained full XCI at
late passage also retained high levels of XIST expression (Fig-
ure S5B). There were two hiPSC clones (iPS3 and iPS7) that
had intermediate levels of XIST expression at late passage
(indicated by dagger in Figure S5B) but showed focal loss of
XCI, consistent with the previously suggested XIST threshold
effect (Figures 5C and 5D). By using allele-specific RT-PCR,
we confirmed that loss of DNA methylation was associatedCell Stem Cell 10, 620–634, May 4, 2012 ª2012 Elsevier Inc. 627
Figure 5. DNA Methylation on the X Chromosome
CpGs are ordered by chromosomal location, with the cytobands indicated to the left of the heatmaps.
(A and B) Hierarchical clustering of all samples according to 27K DNAMethylation array data. Cluster assignments are shown on the enlarged dendrogram above
the heatmaps. XIST expression is shown below the heatmap.
(C) Box and whisker plot of chrX b values in 106 female hPSC samples ordered according to decreasing XIST expression.
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(Figures 6A–6E). We observed loss of XIST expression (and
loss of DNA methylation on the X chromosome) in most of the
hiPSC clones, and retention of XIST expression (with preserva-
tion of X chromosome DNA methylation) in a minority of the
clones, even though all the cloneswere generated and passaged
in the same manner and at the same time. In contrast to the
examined imprinted genes, no significant associations for the
loss of XCI with specific cell culture or derivation conditions
were detected in the multiple linear regression models.
Aberrations in Genomic Imprints and XCI Genes
Are Maintained through Differentiation
If hPSC-specific aberrations in genomic imprints and XCI persist
through differentiation, they may impact the utility of hPSC-
derived cells for cellular transplantation and disease modeling.
Therefore, we assessed the status of such aberrations in undif-
ferentiated and differentiated hPSCs.WA09 hESCswere studied
before and after a 3 day spontaneous differentiation, whereas
WA07, iPS201B7, and iPS414C.2 were studied before and after
more extensive NPC and OPC differentiations. In every case, the
aberrations in imprinting and XCI that were present in the starting
undifferentiated hPSC populations weremaintained, and no new
aberrations arose during the course of differentiation (Figures 7A
and 7B). In our collection of 11 fibroblast-derived hiPSC clones,
loss of XCI was observed in 49 X-linked disease genes by late
passage (OMIM; Figure 7C). These results merit caution in the
use of female hiPSCs for studies of X-linked disease modeling.
DISCUSSION
In this study, we explored epigenetic and transcriptional varia-
tion in the most comprehensive collection of hPSC and somatic
samples to date. By using a combination of genome-wide DNA
methylation and mRNA expression data, we identified unique
epigenetic and transcriptional properties of the pluripotent state.
Most distinctive among these characteristics are prevalent, but
not uniform, losses of imprinting and XCI and consistent hyper-
methylation of somatic cell type-specific genes in hPSCs. We
observed the acquisition of the appropriate cell type-specific
DNA methylation marks during differentiation of hPSCs, despite
persistence of aberrant imprinting and XCI. The scope and reso-
lution of our study has allowed us to address many inconsis-
tencies in the literature, which arose from the inclusion of limited
numbers of cell lines and/or sparse coverage of the genome.
In order to determine which imprinted genes we could confi-
dently analyze in our study, we identified a panel of loci that
showed appropriate imprinting in normal tissue samples, as
well as gynogenetic and androgenetic samples. We observed
aberrations at many of the examined imprinted genes in a
substantial subset of hPSCs; changes at some loci arose during
reprogramming and others over time in culture. Very few studies
have addressed potential causes of aberrant imprinting in
hPSCS (such as culture conditions or derivation methods),(D) XIST expression in parental fibroblasts and 11 hiPSC clones at early, int
reprogramming and a subsequent tendency for loss of XIST expression over tim
(E) DNA methylation (450K DNA Methylation array) for fibroblast, early-passage
See also Figures S4 and S5.although a recent study comparing the hESC line WA09 and
six isogenic WA09-derived hiPSC lines reported that imprinting
of NNAT (as well as XCI) was specifically lost in hiPSCs
compared to hESCs (Teichroeb et al., 2011). Although we iden-
tified NNAT as one of the genes with hPSC-specific variability in
DNA methylation (Figure 1B; Table S2B), none of the observed
variations were specific to hESCs or hiPSCs and none of the
20 CpG sites in the promoter region of NNAT interrogated by
the 27K and 450K DNA Methylation array passed our imprinted
site filters. Using linear regression, we were able to correlate
the imprinting status of DIRAS3, L3MBTL, and PEG3 with
specific in vitro manipulations, whereas the DNA methylation
status of the other imprinted genes in our analysis were indepen-
dent of the identifiable variables. The strongest association seen
was between DIRAS3 hypermethylation and culture in the orig-
inal hESC medium, which contained FBS, in contrast to the
currently used hPSC media, which contain knockout serum
replacement and purified FGF2. Given the limited numbers of
samples and cell lines representing each variable in the regres-
sion models, it will be necessary in future studies to systemati-
cally test specific variables in a well-replicated manner in order
to identify causal relationships between specific derivation/re-
programming and culture conditions and epigenetic aberrations.
We observed a large degree of variability in X chromosome
CpGmethylation in female hPSCs, which appeared to be depen-
dent on the level of XIST expression. Our results were consistent
with a loss of XIST expression with time in culture, followed by
erosion of DNA methylation, originating in several subsegments
of the X chromosome and spreading to involve larger regions.
Our prediction that loss of XCI may affect the fidelity of hPSC-
based X-linked disease models is consistent with the findings
reported in an accompanying manuscript in this issue of Cell
Stem Cell from Mekhoubad et al. (2012). In their studies,
a hiPSC-based disease model of the X-linked disease Lesch-
Nyhan Syndrome lost the ability to recapitulate hallmark
biochemical characteristics of the disease with time in culture.
These researchers showed that this phenomenon was due to
loss of XCI and reactivation of the wild-type HPRT gene in the
late-passage female hiPSCs, consistent with our observations
that loss of XCI at the HPRT locus was a common feature that
occurred in more than half of the female hESC and hiPSC
samples we analyzed.
We found that DNA hypomethylation was the most discrimi-
nate epigenetic feature of any given tissue and that tissue-
specific hypomethylated genes were associated with the
function of that tissue. Among these genes were transcription
factors used for the transdifferentiation of fibroblasts into
neurons, master regulators of oligodendrocyte differentiation,
and iPSC reprogramming factors.We suggest that the identifica-
tion of uniquely hypomethylated genes will permit the discovery
of high-level regulators of cellular identity and may inform the
selection of factors for novel transdifferentiation protocols.
Our results suggest that an interplay between DNA methyla-
tion and demethylation regulates cellular differentiation. Weermediate, and late passages shows an increase in XIST expression after
e in culture.
hiPSC, and late-passage hiPSC samples.
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Figure 6. Allele-Specific Expression of Genes Subject to XCI
Allele-specific expression of genes subject to X-chromosome inactivation in
female hPSC samples: (A)RPGR, (B)MAMLD1, (C)SLC25A43, (D)USP51, and
(E)DDX26B. hPSC samples are represented as squares and each data point is
colored according to the average b value for that gene shown in the heatmap to
the right; data points without corresponding DNA methylation data are white.
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tion of hPSCs into NPCs and OPCs that recapitulated patterns
of DNA methylation at neural and oligodendrocyte-specific
genes in fetal and adult brain samples, supporting the validity
of hPSCs as models of development and disease. For example,
dysregulation of QKI (KH domain-containing RNA binding factor
‘‘quaking homolog’’) is strongly associated with schizophrenia
(Aberg et al., 2006). QKI was uniquely hypomethylated in fetal
and adult brain samples in our data, so the demethylation of
this gene observed during neural differentiation of hPSCs
may be a necessary feature for accurate in vitro modeling of
schizophrenia.
By studying genome-wide DNAmethylation and gene expres-
sion profiles in a large and diverse collection of pluripotent and
somatic samples, we have discovered that pluripotent cells differ
from somatic cells at sites in the genome that are generally
considered to be epigenetically stable: the inactivated X chro-
mosome in female cells and imprinted loci. Among pluripotent
cultures, there was a large degree of variation at these sites,
and their methylation status was not changed with differentia-
tion. These epigenetic instabilities merit a degree of caution in
the interpretation of X-linked hPSC-based disease models and
indicate that hPSC derivatives destined for clinical use should
be examined for aberrations in imprinting and XCI. Therefore,
identification of specific culture conditions or small molecules
that promote the stability of genomic imprints and XCI over
long-term culture would be of great value to the stem cell
community.
EXPERIMENTAL PROCEDURES
Sample Collection and Culture Conditions
All samples were either cultured in house or obtained from collaborators (for
sample details, see Table S1). The human pluripotent stem cell aspect of the
research was performed under a protocol approved by the UCSD Embryonic
Stem Cell Research Oversight Committee and the TSRI Institutional Review
Board. Human tissues were collected under a protocol approved by the
UCSD Institutional Review Board. Plat-A Packaging cells (Cell Biolabs, Inc.)
were maintained according to the manufacturer’s instructions. Human dermal
fibroblasts (HDFs, ScienCell Research Laboratories) were cultured in Dulbec-
co’s modified eagle medium, 2 mM GlutaMax, 10% fetal bovine serum, and
0.1 mM nonessential amino acids (Life Technologies, Inc.). Culture conditions
for hPSCs are listed in Table S1.
Generation of iPSCs
PLAT-A packaging cells were plated onto six-well plates coated with poly-D-
lysine at a density of 1.53 106 cells per well without antibiotics and incubated
overnight. Cells were transfected with 4 mg of moloney murine leukemia-based
retroviral vectors (pMXs) containing the human cDNA of POU5F1, SOX2,
KLF4, or MYC (Addgene) using Lipofectamine 2000 (Life Technologies,
Inc.) according to the manufacturer’s instructions. Viral supernatants were
collected at 48 and 72 hr posttransfection, filtered through a 0.45 mm pore-
size filter. 150,000 HDFs were seeded onto each well of a six-well plate over-
night. Equal volumes of fresh 48 hr and 72 hr viral polybrene-supplemented
(6 mg/ml, Sigma) supernatants were added onto the cells at 24 hr and 48 hr
postseeding. On day 3, the transduced cells were split onto MEFs at a density
of 104 cells per well of a six-well plate in hESC medium supplemented withRed arrows identify HDF51 iPSC lines that switched from monoallelic
expression at early passages to biallelic expression at late passages. Genomic
DNA and no template (NT) controls are plotted as blue diamonds. Error bars
indicate the standard error.
Figure 7. Implications of Aberrations in XCI and Genomic Imprints on Disease Modeling
(A) DNA methylation (450K DNA Methylation array) of 214 gametic imprinted CpG sites at imprinted loci for control androgenetic and gynogenetic samples,
undifferentiated (labeled with green text), and differentiated (labeled with red text) hPSC samples. Arrows indicate direction of differentiation.
(B) The heatmap shows DNA methylation (450K DNA Methylation array) on the X chromosome for control male tissue samples, control female tissue samples,
undifferentiated samples (labeled with green text), and differentiated samples (labeled with red text) hPSC samples. Arrows indicate direction of differentiation.
CpGs are ordered by chromosomal location, with the cytobands indicated to the left of the heatmap.
(C) Diagram indicating the frequency of loss of XCI at X-linked disease genes among 11 hiPSC clones reprogrammed from the same fibroblast culture. The
number of clones showing loss of XCI at each locus is listed to the right of the gene name. Genes with loss of XCI in 1–3 clones are shown in black, in 4–5 clones in
orange, and in 6–8 clones in red.
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Recurrent Variations in DNA Methylation0.5 mM Valproic Acid (VPA, Stemgent). Cells were fed every other day with
hESC medium + VPA for 14 days. iPSC colonies were picked 3 weeks post-
transduction and transferred onto MEF plates.
In Vitro Differentiation
For spontaneous embryoid body (EB) formation, hPSCs were manually
passaged to low-attachment plates in hESC medium without bFGF for
7 days, changing media every other day. On day 8, EBs were transferred
onto gelatin-coated coverslips and cultured in the same medium for 7 more
days. Directed differentiation was performed as previously described (Harness
et al., 2011; Nistor et al., 2005).
Immunocytochemistry
Cells were fixed with 4%paraformaldehyde in PBS for 15min, washed 33with
PBS, and blocked in PBS with 2% BSA (Sigma), 0.1% Triton X-100, and 2%
low-fat milk for 30 min at room temperature. Primary antibodies include
POU5F1, NANOG, BRACHYURY (Santa Cruz; 1:100, 1:100, 1:300); TRA1-81
(1:100, Stemgent); MAP2, AFP, NESTIN, SMA (Millipore; 1:100, 1:400,
1:2,000, 1:10,000); and PAX6, NESTIN, OLIG1, GALC, A2B5 (Chemicon;
1:200, 1:200, 1:200, 1:200, 1:500). Fluorescence conjugated secondary anti-
bodies were used according to manufacturer’s protocol (Life Technologies,
Molecular Probes). Images were obtained with IX51 Olympus and Nikon
Eclipse Ti microscopes.
Teratoma Assay
1 3 106 HDF51iPS cells were harvested by Accutase treatment (Life Technol-
ogies, Inc.), resuspended in a 1:1 mixture of DMEM/F12 and Matrigel (BD
Biosciences), and injected into the right testis of a C.B-17-Prkdcscid mouse
(Charles River). 6–8 weeks after injection, tumors were dissected, fixed in
4% PFA, sectioned, and stained with hematoxylin and eosin.
DNA Methylation Profiling
DNAwas extracted from 13 106 cells (QIAGEN DNeasy Blood and Tissue Kit),
quantified (Qubit dsDNA BR Assay Kits, Life Technologies, Inc.), quality
controlled (DNA1000 Kit and BioAnalyzer 2100, Agilent), and bisulfate
converted (EZ DNAMethylation Kit, Zymo Research) according to eachmanu-
facturer’s protocol. Bisulfite converted DNA was hybridized to Infinium
HumanMethylation27K and Infinium 450K BeadChips (Illumina, Inc.), scanned
with an iScan (Illumina, Inc.), and quality controlled in GenomeStudio. For 27K
data, b values for each probe were range-scaled with data collected from DNA
controls that were fully methylated (SSI DNA methyltransferase treated [NEB],
bisulfite converted DNA), unmethylated (untreated genomic DNA), and half-
methylated (50/50 mix of methylated and unmethylated controls). 450K data
was background subtracted and normalized to controls in GenomeStudio.
Hierarchical clustering was performed with Cluster, with Euclidian distance
and complete linkage.
Expression Profiling
Total RNA was extracted from snap-frozen sample pellets (Ambion mirVana
Kit, Life Technologies, Inc.) according to the manufacturer’s protocol. RNA
quantity (QubitTM RNA BR Assay Kits, Life Technologies, Inc.) and quality
(RNA6000 Nano Kit and Bioanalyzer 2100, Agilent) was determined to be
optimal for each sample prior to further processing. 200 ng RNA per sample
was amplified with the Total PrepTM RNA Amplification Kit (Illumina, Inc.) ac-
cording to manufacturer’s protocol and quantified as above. 750 ng labeled
RNA/sample was hybridized to HT-12v3 Expression BeadChips (Illumina,
Inc.), scanned with an iScan (Illumina, Inc.). In GenomeStudio, probes were
filtered for those detected at p < 0.01 in at least one sample and exported for
normalization in R via robust spline normalization (RSN). Hierarchical clustering
was performed with Cluster, with Euclidian distance and complete linkage.
Identification of DNA Methylation Probes for Imprinted Genes
CpG probes that were reciprocally methylated in gynogenetic (ovarian tera-
toma and parthenotes; entirely of maternal origin) and androgenetic (complete
hydatidiform moles; entirely of paternal origin), partially methylated in tissue
samples (stable imprinting), and associated with imprinted genes (according
to http://www.geneimprint.com) were identified as gametic imprints (Fig-
ure S4). For range-scaled 27K DNA Methylation array data, we supplemented632 Cell Stem Cell 10, 620–634, May 4, 2012 ª2012 Elsevier Inc.our data with published data from an ovarian teratoma and three hydatidiform
mole samples (Choufani et al., 2011). All imprinted probes were partially
methylated (0.25<b<0.75) in at least 75%of tissue samples.Maternal imprints
were unmethylated (b < 0.09) in at least two androgenetic samples and fully
methylated (b > 0.85) in at least two gynogenetic samples. Paternal imprints
were unmethylated (b < 0.09) in at least two gynogenetic samples and fully
methylated (b > 0.85) in at least two androgenetic samples (Table S5A).
Because of differences in normalization, the criteria for identification
of imprinted probes were slightly different for the 450K DNA Methylation array
data.CpGprobeswere annotated to imprinted geneswith the 450KDNAMeth-
ylation array manifest file, or if it fell within 5 kb upstream of the gene according
to UCSC hg18. All imprinted probes were partially methylated (0.20 < b < 0.80)
in at least 90% of tissue samples. Maternal imprints were unmethylated (b <
0.20) in at least two androgenetic samples and fully methylated (b > 0.80) in
at least two gynogenetic samples. Paternal imprints were unmethylated (b <
0.20) in at least two gynogenetic samples and fully methylated (b > 0.80) in at
least two androgenetic samples (Table S5B).
Identification of DNA Methylation Probes for X-Inactivated Regions
In order to select for X chromosome CpG sites subject to XCI on the 27K DNA
Methylation array, we first removed probes for sites in the pseudoautosomal
regions of the X chromosome and then selected the X chromosome probes
that were partially methylated (b values between 0.09 and 0.85) in at least
75% of the female tissue samples and unmethylated (b value less than 0.09)
in at least 75% of the male tissue samples. 452 X chromosome DNA methyla-
tion probes representing 289 genes passed these filters, of which 293 probes
for 199 genes were anticorrelated with gene expression (Table S5C). To iden-
tify probes subject to XCI on the 450K DNA Methylation array, we filtered for
probes that were partially methylated (0.2 < b < 0.8) in 90% of female tissues
and unmethylated (b < 0.2) 90% male tissues (Table S5D).
Allele-Specific RT-PCR
Informative heterozygous SNPs in the mRNA region of selected X chromo-
some and imprinted genes were identified with microarray SNP genotyping
data (Laurent et al., 2011). Total RNA was collected as above and converted
to cDNA (Quantitect Reverse Transcription Kit, QIAGEN) according to the
manufacturer’s protocol. 40 ng of cDNA was then used as input for a Taqman
qPCR SNP genotyping array selected to determine allelic expression.
Quantitative expression data were acquired and analyzed with a CFX-96
Real-Time PCR Detection System (BIORAD) with the SNP genotyping taqman
probes DDX26B (C_16188987_10), MAMLD1 (C_15867801_10), RPGR
(C_11874860_10), SLC25A43 (C_25953804_20), USP51 (C_27476233_10),
PEG10 (C_25805777_10), and PEG3 (C_25643544_10).
Functional Enrichment Analysis
Functional enrichment analysis was performed with GREAT (McLean et al.,
2010). The basal+extension setting was used with all CpG probes on the
27K or 450K DNA Methylation array (except for those on X and Y) used as
the background set.
ACCESSION NUMBERS
All DNA methylation and gene expression array data are available at the NCBI
GEO database under the accession designation GSE30654. Previously
published 27K DNAMethylation array data from an ovarian teratoma and three
hydatidiform mole samples are available at the NCBI GEO database under the
accession designation GSE22091.
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found with this article online at doi:10.1016/j.stem.2012.02.013.
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